72 related articles for article (PubMed ID: 1988506)
1. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine.
Wintsch J; Chaignat CL; Braun DG; Jeannet M; Stalder H; Abrignani S; Montagna D; Clavijo F; Moret P; Dayer JM
J Infect Dis; 1991 Feb; 163(2):219-25. PubMed ID: 1988506
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
[TBL] [Abstract][Full Text] [Related]
3. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein.
Bui T; Dykers T; Hu SL; Faltynek CR; Ho RJ
J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):799-806. PubMed ID: 8021814
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.
Kahn JO; Sinangil F; Baenziger J; Murcar N; Wynne D; Coleman RL; Steimer KS; Dekker CL; Chernoff D
J Infect Dis; 1994 Nov; 170(5):1288-91. PubMed ID: 7963729
[TBL] [Abstract][Full Text] [Related]
5. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
Dolin R; Graham BS; Greenberg SB; Tacket CO; Belshe RB; Midthun K; Clements ML; Gorse GJ; Horgan BW; Atmar RL
Ann Intern Med; 1991 Jan; 114(2):119-27. PubMed ID: 1984386
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE
Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389
[TBL] [Abstract][Full Text] [Related]
7. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies.
Haigwood NL; Shuster JR; Moore GK; Lee H; Skiles PV; Higgins KW; Barr PJ; George-Nascimento C; Steimer KS
AIDS Res Hum Retroviruses; 1990 Jul; 6(7):855-69. PubMed ID: 2390335
[TBL] [Abstract][Full Text] [Related]
8. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
[TBL] [Abstract][Full Text] [Related]
9. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
10. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
[TBL] [Abstract][Full Text] [Related]
11. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of immunoadjuvant conjugates with HIV-derived peptide inducing peptide-specific antibody.
Maruyama Y; Kurimura M; Achiwa K
Chem Pharm Bull (Tokyo); 1994 Aug; 42(8):1709-11. PubMed ID: 7954925
[No Abstract] [Full Text] [Related]
13. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.
Locher CP; Grant RM; Collisson EA; Reyes-Terán G; Elbeik T; Kahn JO; Levy JA
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1685-9. PubMed ID: 10606091
[TBL] [Abstract][Full Text] [Related]
14. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine.
Burke RL; Goldbeck C; Ng P; Stanberry L; Ott G; Van Nest G
J Infect Dis; 1994 Nov; 170(5):1110-9. PubMed ID: 7963702
[TBL] [Abstract][Full Text] [Related]
15. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens.
Ullrich SE; Fidler IJ
J Leukoc Biol; 1992 Nov; 52(5):489-94. PubMed ID: 1431559
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences.
Nitayaphan S; Khamboonruang C; Sirisophana N; Morgan P; Chiu J; Duliege AM; Chuenchitra C; Supapongse T; Rungruengthanakit K; deSouza M; Mascola JR; Boggio K; Ratto-Kim S; Markowitz LE; Birx D; Suriyanon V; McNeil JG; Brown AE; Michael RA
Vaccine; 2000 Feb; 18(15):1448-55. PubMed ID: 10618542
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
Salmon-Céron D; Excler JL; Finkielsztejn L; Autran B; Gluckman JC; Sicard D; Matthews TJ; Meignier B; Valentin C; El Habib R; Blondeau C; Raux M; Moog C; Tartaglia J; Chong P; Klein M; Milcamps B; Heshmati F; Plotkin S
AIDS Res Hum Retroviruses; 1999 May; 15(7):633-45. PubMed ID: 10331442
[TBL] [Abstract][Full Text] [Related]
18. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
Evans TG; Keefer MC; Weinhold KJ; Wolff M; Montefiori D; Gorse GJ; Graham BS; McElrath MJ; Clements-Mann ML; Mulligan MJ; Fast P; Walker MC; Excler JL; Duliege AM; Tartaglia J
J Infect Dis; 1999 Aug; 180(2):290-8. PubMed ID: 10395842
[TBL] [Abstract][Full Text] [Related]
19. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant.
Keitel W; Couch R; Bond N; Adair S; Van Nest G; Dekker C
Vaccine; 1993; 11(9):909-13. PubMed ID: 8212835
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
